BioLuminate seeks capital for breast probe
This article was originally published in Clinica
Executive Summary
BioLuminate, a small company that has developed a quick and minimally invasive probe for the detection of breast cancer, is struggling to survive as it faces funding problems in a recessive market. The Pleasanton, California-based company has raised $4.4m from angel investors, but needs a further $23m to bring its product to market.